{"product_id":"immunocore-marketing-mix","title":"Immunocore Marketing Mix","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGet Inspired by a Complete Brand Strategy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eDiscover how Immunocore leverages its innovative therapies, strategic pricing, targeted distribution, and impactful promotional efforts to dominate the biopharmaceutical market.\u003c\/p\u003e\n\u003cp\u003eUnlock the full potential of this analysis to understand Immunocore's competitive edge and apply similar strategies to your own business.\u003c\/p\u003e\n\u003cp\u003eGet instant access to a professionally written, editable 4Ps Marketing Mix report, saving you hours of research and providing actionable insights.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eroduct\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eKIMMTRAK (tebentafusp-tebn)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eKIMMTRAK, Immunocore's pioneering bispecific immunotherapy, represents a significant advancement in treating unresectable or metastatic uveal melanoma (mUM) in adults. Its unique mechanism leverages the body's T cells to target and destroy cancer cells, offering a novel therapeutic approach.\u003c\/p\u003e\n\u003cp\u003eAs of early 2025, KIMMTRAK's market penetration is robust, with approvals secured in 39 countries and active launches in 26. This widespread adoption underscores its growing importance as a recognized standard of care for mUM patients worldwide.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eImmTAC Platform Technology\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe ImmTAC platform is the heart of what Immunocore offers, creating a new kind of medicine. These are bispecific biologics, meaning they have two distinct functions. They're designed to find specific disease cells and then bring the body's own T cells, which are immune cells, to attack those diseased cells.\u003c\/p\u003e\n\u003cp\u003eThis technology is incredibly adaptable. Immunocore can use it to develop treatments for a wide range of conditions. This includes not only cancer but also infectious diseases and autoimmune disorders, showcasing its broad potential in medicine.\u003c\/p\u003e\n\u003cp\u003eAs of early 2024, Immunocore had several ImmTAC candidates in clinical development, with a focus on advancing its lead oncology programs. For instance, its flagship therapy, Kimmtrak, approved for advanced uveal melanoma, is a testament to the platform's ability to deliver approved treatments.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOncology Pipeline Expansion\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunocore's oncology pipeline expansion extends beyond KIMMTRAK, showcasing a commitment to broad cancer coverage.  The company is progressing ImmTAC candidates like brenetafusp (IMC-F106C), which is currently in a Phase 3 trial for first-line advanced cutaneous melanoma.  This strategic move aims to build upon their existing success and address significant unmet needs in solid tumor treatment.\u003c\/p\u003e\n\u003cp\u003eFurther strengthening their portfolio, Immunocore is developing IMC-R117C, targeting PIWIL1, for indications including colorectal and other gastrointestinal cancers. This focus on diverse solid tumors highlights Immunocore's strategy to leverage its ImmTAC technology across a wider range of difficult-to-treat cancers, potentially capturing a larger market share in the oncology space.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInfectious Disease Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunocore is extending its ImmTAC technology into the infectious disease arena with its ImmTAV platform. This innovative approach aims to create immune-mobilizing monoclonal TCRs against viruses, showcasing the broad applicability of their core science. \u003c\/p\u003e\n\u003cp\u003eThe company has two key clinical candidates targeting viral infections: IMC-M113V for a functional cure in HIV and IMC-I109V for Hepatitis B Virus (HBV). These programs highlight Immunocore's commitment to addressing significant unmet medical needs beyond its established oncology focus. \u003c\/p\u003e\n\u003cp\u003eThe potential market for effective HIV and HBV treatments is substantial, with millions affected globally. For instance, in 2023, an estimated 39 million people were living with HIV worldwide, and the World Health Organization reported that in 2022, approximately 296 million people were living with chronic HBV infection. \u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct:\u003c\/strong\u003e Infectious Disease Programs utilizing ImmTAV technology.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eKey Candidates:\u003c\/strong\u003e IMC-M113V (HIV functional cure) and IMC-I109V (HBV).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Potential:\u003c\/strong\u003e Addressing millions of patients globally living with HIV and HBV.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTechnology:\u003c\/strong\u003e ImmTAC platform adapted for viral targets, demonstrating versatility.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAutoimmune Disease Candidates\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eImmunocore is strategically diversifying its pipeline by entering the autoimmune disease arena with novel bispecific candidates. This move leverages their established technology platform to address significant unmet needs in conditions like Type 1 Diabetes and atopic dermatitis.\u003c\/p\u003e\n\u003cp\u003eKey candidates in this expansion include IMC-S118AI for Type 1 Diabetes and IMC-U120AI for atopic dermatitis, both currently in preclinical development. Regulatory submissions, specifically CTA\/IND filings, are targeted for late 2025 and 2026, respectively, marking important milestones in their development journey.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003ePipeline Expansion:\u003c\/strong\u003e Entry into autoimmune disease market with bispecific candidates.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eKey Candidates:\u003c\/strong\u003e IMC-S118AI (Type 1 Diabetes) and IMC-U120AI (atopic dermatitis).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDevelopment Stage:\u003c\/strong\u003e Both candidates are in preclinical development.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eRegulatory Milestones:\u003c\/strong\u003e CTA\/IND submissions planned for late 2025 (IMC-S118AI) and 2026 (IMC-U120AI).\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Product-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNew Standard of Care for Uveal Melanoma Expands Reach\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eKIMMTRAK (tebentafusp-tebn) is Immunocore's flagship product, an FDA-approved bispecific protein targeting HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma (mUM). Its unique ImmTAC technology enables it to bind to both tumor cells and T cells, orchestrating an immune response. As of early 2025, KIMMTRAK has secured approvals in 39 countries, with active launches in 26, solidifying its position as a critical treatment option for mUM.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003eIndication\u003c\/th\u003e\n\u003cth\u003eTechnology\u003c\/th\u003e\n\u003cth\u003eApproval Status (Early 2025)\u003c\/th\u003e\n\u003cth\u003eKey Market Data\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eKIMMTRAK (tebentafusp-tebn)\u003c\/td\u003e\n\u003ctd\u003eUnresectable or metastatic uveal melanoma (mUM)\u003c\/td\u003e\n\u003ctd\u003eImmTAC (Bispecific Protein)\u003c\/td\u003e\n\u003ctd\u003eApproved in 39 countries, launched in 26\u003c\/td\u003e\n\u003ctd\u003eRecognized standard of care for mUM\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eThis analysis provides a comprehensive overview of Immunocore's marketing strategies, examining their product innovation, pricing models, distribution channels, and promotional efforts within the competitive biopharmaceutical landscape.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSimplifies complex marketing strategies into actionable insights, alleviating the burden of deciphering intricate plans.\u003c\/p\u003e\n\u003cp\u003eProvides a clear, concise overview of Immunocore's 4Ps, addressing the pain point of information overload for busy executives.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003elace\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Commercialization of KIMMTRAK\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore has successfully commercialized KIMMTRAK globally, achieving launches in 26 countries and securing approvals in 39 countries by March 31, 2025. This extensive market penetration, including key regions like the United States, Europe, Canada, and Australia, signifies a robust strategy to make the therapy accessible to a wide patient population.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect Sales Force and Distribution Network\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eImmunocore leverages a dedicated, internalized sales force in the U.S. to promote KIMMTRAK, aiming for deep market penetration and sustained growth. This direct engagement strategy allows for targeted outreach to healthcare professionals.\u003c\/p\u003e\n\u003cp\u003eThis direct sales model in the U.S. ensures efficient distribution and a focused approach to market development for KIMMTRAK. For international markets, Immunocore utilizes a complementary network to extend its reach and product availability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Partnerships and Collaborations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunocore actively pursues strategic partnerships to amplify its market presence and extend its global reach. These alliances are crucial for advancing its innovative therapies and ensuring wider patient access.\u003c\/p\u003e\n\u003cp\u003eA prime example is the EORTC-sponsored ATOM trial for KIMMTRAK in adjuvant uveal melanoma. This collaboration, ongoing in 2024, underscores Immunocore's commitment to expanding the clinical utility of its lead asset and reaching more patients in need.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy and Hospital Channels\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eImmunocore's KIMMTRAK, a specialized immunotherapy, necessitates distribution through carefully managed channels. This ensures the complex treatment reaches the right patients safely and effectively.\u003c\/p\u003e\n\u003cp\u003eThe primary distribution pathways for KIMMTRAK are specialty pharmacy networks and hospital systems. These channels are equipped to handle the unique storage, administration, and patient support requirements of advanced therapies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecialty Pharmacy Networks:\u003c\/strong\u003e These pharmacies are crucial for managing high-cost, complex medications, offering services like patient education, adherence support, and insurance navigation.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHospital Channels:\u003c\/strong\u003e Hospitals provide the clinical infrastructure for administering KIMMTRAK, including infusion centers and oncology departments, ensuring close medical supervision.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePatient Access:\u003c\/strong\u003e This dual-channel approach aims to maximize patient access while maintaining the integrity and efficacy of the treatment throughout the supply chain.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Trial Sites for Pipeline Products\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eImmunocore's 'Place' strategy for its pipeline products centers on building a robust global clinical trial network. This is crucial for efficiently enrolling patients and gathering high-quality data across its diverse therapeutic areas, including oncology, infectious diseases, and autoimmune disorders.\u003c\/p\u003e\n\u003cp\u003eThe company actively manages its presence in key geographical regions to facilitate patient access and data integrity for its ongoing Phase 1, Phase 2, and Phase 3 studies. This strategic placement of trial sites is fundamental to advancing its innovative T-cell receptor (TCR) bispecific immunotherapies through the development pipeline.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eGlobal Trial Site Expansion:\u003c\/strong\u003e Immunocore is strategically expanding its clinical trial footprint across North America, Europe, and Asia to maximize patient enrollment for its pipeline candidates.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePhase-Specific Site Management:\u003c\/strong\u003e The company meticulously selects and manages trial sites based on the specific requirements of Phase 1, Phase 2, and Phase 3 studies, ensuring optimal patient populations and data collection.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eTherapeutic Area Focus:\u003c\/strong\u003e Site selection is tailored to indications such as advanced melanoma, non-small cell lung cancer, and other solid tumors, as well as potential applications in infectious diseases and autoimmune conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eData Quality and Regulatory Compliance:\u003c\/strong\u003e A key aspect of Immunocore's 'Place' strategy is ensuring all trial sites adhere to the highest standards of data quality and regulatory compliance, critical for successful drug development and eventual market approval.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/MARKETING-MIX-Content-Place-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Distribution: Global Reach for Complex Therapies\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eImmunocore's 'Place' strategy for KIMMTRAK involves a dual-channel approach: direct sales in the U.S. via an internalized sales force and partnerships for international markets. This ensures both focused engagement and broad global reach. The distribution relies on specialty pharmacies and hospital systems, chosen for their ability to manage complex, high-value therapies and provide essential patient support.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eDistribution Channel\u003c\/th\u003e\n\u003cth\u003eKey Role\u003c\/th\u003e\n\u003cth\u003eGeographic Focus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty Pharmacy Networks\u003c\/td\u003e\n\u003ctd\u003ePatient education, adherence support, insurance navigation\u003c\/td\u003e\n\u003ctd\u003eU.S. and International\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospital Systems\u003c\/td\u003e\n\u003ctd\u003eInfusion centers, oncology departments, clinical supervision\u003c\/td\u003e\n\u003ctd\u003eU.S. and International\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInternalized Sales Force\u003c\/td\u003e\n\u003ctd\u003eTargeted outreach to healthcare professionals\u003c\/td\u003e\n\u003ctd\u003eU.S. only\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStrategic Partnerships\u003c\/td\u003e\n\u003ctd\u003eExpanding global reach and market access\u003c\/td\u003e\n\u003ctd\u003eInternational\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003eImmunocore 4P's Marketing Mix Analysis\u003c\/h2\u003e\n\u003cp\u003eThe preview you see here is the actual, complete Immunocore 4P's Marketing Mix Analysis you'll receive instantly after purchase. This ensures you know exactly what you're getting – a ready-to-use document with no hidden surprises. You can confidently assess the depth and quality of the analysis before making your decision.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":55612335653241,"sku":"immunocore-marketing-mix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/immunocore-marketing-mix.png?v=1754770596","url":"https:\/\/growthsharematrix.com\/products\/immunocore-marketing-mix","provider":"Growth Share Matrix","version":"1.0","type":"link"}